Novel compounds as CK2 inhibitors for disease treatment

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing novel compounds designed to inhibit Casein Kinase 2 alpha (CK2α). The application, US20260085062A1, describes specific chemical structures (Formula I) and their potential therapeutic applications in treating diseases such as cancer, viral infections, inflammation, diabetes, and neurodegenerative conditions. It also covers pharmaceutical compositions containing these compounds.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in drug discovery within the pharmaceutical sector. Companies involved in oncology, virology, and neurology research may find this application relevant for competitive intelligence and R&D strategy.

Source document (simplified)

← USPTO Patent Applications

NOVEL COMPOUNDS AS CK2 INHIBITORS

Application US20260085062A1 Kind: A1 Mar 26, 2026

Inventors

Paul Glossop, Marko Juhana Hyvonen, Paul Brear, David Robert Spring

Abstract

Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.

CPC Classifications

C07D 403/14 A61K 31/416 A61K 31/4196 A61K 31/422 A61K 31/4245 A61K 31/433 A61K 31/4439 A61K 31/444 A61K 31/501 C07D 231/56 C07D 401/04 C07D 401/14 C07D 403/04 C07D 403/12 C07D 405/04 C07D 413/04 C07D 413/14 C07D 417/04 C07D 471/04